Overview
- Plaintiff law firms have filed a securities class action accusing GRAIL of violating Section 10(b), Section 20(a) and SEC Rule 10b‑5 by making allegedly misleading public statements about the NHS‑Galleri cancer‑screening trial.
- The complaint says GRAIL overstated the trial’s prospects, failed to disclose detailed topline data and that a three‑year follow‑up was insufficient to show reductions in Stage III–IV cancers.
- Rosen Law Firm, The Schall Law Firm and other firms publicly solicited investors on July 12–13, 2026 and warned that prospective lead plaintiffs must move the court by August 4, 2026 to seek appointment.
- No class has been certified and investors are not represented unless they retain counsel, meaning affected shareholders must act to participate or to seek lead‑plaintiff status.
- If the case proceeds it could clarify disclosure duties for clinical trials, affect investor recovery chances depending on certification or settlement, and prompt scrutiny of how companies release interim trial data.